Pharmacy Costs Are Spiking Again — What Employers Should Do About Brand Name Drugs and GLP 1s
Brand Name Drug Inflation Is Back in Force
Pharmacy costs are rising again, and employers are feeling the pressure. Brand name drugs now account for more than half of total pharmacy spend, even though they represent a small fraction of total prescriptions. In 2026, price increases accelerated across several therapeutic classes, including autoimmune conditions, oncology, and diabetes. At the same time, GLP 1 medications for weight loss and diabetes management have become one of the fastest growing cost drivers in employer plans.
The result is a familiar challenge: employees need access to effective medications, but employers must keep plans financially sustainable. Pharmacy inflation is not expected to slow in 2027, so benefits managers are looking for practical ways to manage costs without reducing care quality.
GLP 1s Are Reshaping Pharmacy Spend
GLP 1 medications such as semaglutide and tirzepatide have transformed diabetes management and weight loss treatment. They are clinically effective, but they are also expensive, often costing more than $1,000 per month per member. Utilization continues to rise, driven by strong employee demand, expanded clinical guidelines, and aggressive direct to consumer marketing.
Employers are wrestling with three questions:
- Should we cover GLP 1s for weight loss?
- How do we manage long term adherence and cost?
- What guardrails should we put in place?
There is no one size fits all answer, but employers are increasingly adopting structured coverage policies that balance access with cost control.
Plan Design Can Rein In Costs Without Reducing Access
The most effective pharmacy strategies focus on plan design, vendor coordination, and member guidance. Employers are finding success with a combination of formulary management, utilization controls, and education.
Three approaches are gaining traction:
- Step therapy and prior authorization. These tools ensure members try clinically appropriate, lower cost options before moving to high cost brand name drugs or GLP 1s.
- Condition based coverage. Some employers cover GLP 1s only for diabetes or only when certain clinical criteria are met.
- Pharmacy carve outs and specialty drug programs. These programs negotiate better pricing and provide tighter oversight for high cost medications.
Another emerging strategy is pairing GLP 1 coverage with structured lifestyle programs. When employees receive coaching, nutrition support, and follow up care, adherence improves and long term outcomes are better. This reduces waste and helps ensure the medication is used appropriately.
Better Navigation Leads to Better Decisions
Employees often struggle to understand the difference between brand name, specialty, and generic medications. They may not know that a clinically equivalent generic exists or that a preferred alternative is available at a lower cost. Pharmacy navigation tools can help employees compare options, understand pricing, and make informed decisions.
Communication is equally important. Benefits managers should highlight preferred pharmacies, explain formulary tiers, and promote cost saving programs during open enrollment and throughout the year. Short guides, FAQs, and simple “how to check your drug cost” instructions can make a meaningful difference.
Prepare Now for 2027 Pricing Trends
Pharmacy inflation is expected to continue, and GLP 1 utilization will likely rise further as new indications are approved. Employers that take a proactive approach now — reviewing plan design, strengthening navigation, and coordinating with pharmacy benefit managers — will be better positioned to manage costs in 2027.
Pharmacy strategy is no longer just about managing prescriptions. It’s about guiding employees toward safe, effective, and affordable care. With the right guardrails and communication, employers can support employee health while keeping pharmacy spend under control.
Musculoskeletal Claims Surge: What Employers Should Do Before 2027
Mental Health Utilization Is Rising Again — How Employers Can Expand Access Without Overspending
Pharmacy Costs Are Spiking Again — What Employers Should Do About Brand Name Drugs and GLP 1s
Financial Wellness as a Core Benefit: Helping Employees Navigate Inflation and Debt
The information presented and conclusions within are based upon our best judgment and analysis. It is not guaranteed information and does not necessarily reflect all available data. Web addresses are current at time of publication but subject to change. SmartsPro Marketing and The Insurance 411 do not engage in the solicitation, sale or management of securities or investments, nor does it make any recommendations on securities or investments. This material may not be quoted or reproduced in any form without publisher's permission. All rights reserved. ©2026 Smarts Publishing https://smartspublishing.com/ Tel. 877-762-7877.